

Fig. 4. Real time PCR analysis. Effect of AxMek<sup>CA</sup> and AxRas<sup>DN</sup> infection on mRNA levels of ALP, OCN, OPN, BSP, Col I, PC-1 and ANK was determined by real time PCR after 2 days of infection in MLO-A5 cells. Effects of these adenoviruses on OPN mRNA expression were also examined in MC3T3-E1 cells overexpressing *runx2* gene. \*Significantly different from AxLacZ-infected cells,  $p < 0.05$ .

inhibition of Erk activity by expressing dominant negative Erk1 suppressed osteoblast differentiation and matrix mineralization by reducing ALP activity and the deposition of bone matrix proteins [16]. These contradictory results are at least partly due to the difficulty in examining the mineralization process independently of the osteoblast differentiation.

Using preosteocytic cell-line MLO-A5 cells and osteoblastic MC3T3-E1 cells, we investigated the direct role of Erk pathways on the mineralization process. MLO-A5 cells are known to mineralize even without  $\beta$ -GP or ascorbic acid, and treating the cells with Mek inhibitor PD98059 stimulated mineralization (Fig. 1), while PDGF treatment, which strongly stimulates these pathways, suppressed it (Fig. 2A). The inhibitory effect of PDGF was reversed by PD98059 or AxRas<sup>DN</sup> infection, indicating a critical involvement of Erk pathways (Figs. 2B and C). Direct activation of Erk pathways by adenovirus vector-mediated Mek<sup>CA</sup> expression suppressed the

mineralization of MLO-A5 cells, and inhibition of the pathways by Ras<sup>DN</sup> expression increased it. Overexpression of Runx2 markedly promoted the terminal differentiation and mineralization of osteoblastic MC3T3-E1 cells, while Mek<sup>CA</sup> expression suppressed and Ras<sup>DN</sup> expression promoted their mineralization. Similar effects of these viruses were observed in primary osteoblasts (data not shown). Importantly, Erk activity regulates the skeletal mineralization in vivo as well. Injecting AxMek<sup>CA</sup> onto the calvaria of 1-day-old mice suppressed, while AxRas<sup>DN</sup> injection promoted the mineralization of calvaria. These results suggest that the Erk activation negatively regulates mineralization of osteoblasts or osteocytes not only in vitro but also in vivo, although the effect of the viruses on other types of cells cannot be ruled out. The exact regulatory mechanism of mineralization by Erk pathways still remains unclear. We found that Erk activation significantly increased OPN expression in MLO-A5 cells. Using an in vitro mineralization assay system,




Fig. 5. In vivo mineralization assay. (A) X-gal staining of mouse calvaria injected with either normal saline (left) or AxLacZ (right). (B) Histological analysis of AxLacZ-injected mouse calvaria stained for  $\beta$ -galactosidase activity. (C–G) Normal saline (D), AxLacZ (E), AxMek<sup>CA</sup> (F) or AxRas<sup>DN</sup> (G) was injected onto the calvaria of 1-day-old ddY mice. Five days after the injection, mice were sacrificed and the rectangular areas of the calvaria (C) were subjected to Alizarin Red staining. Experiments were repeated four times with almost the same results, and representative pictures are shown. Arrows indicate the thickness of the calvaria. Scale bars=100  $\mu$ m.

Hunter et al. demonstrated that OPN suppressed hydroxyapatite formation and that treatment of OPN with ALP reduced its mineralization-inhibitory activity [11,12]. Therefore, it is possible that Erk pathways regulate the mineralization of osteoblasts/osteocytes by regulating OPN expression in the cells. Experiments using OPN deficient mice will clarify the role of the molecule in the mineralization process in the future. We also found that MEK<sup>CA</sup> expression significantly reduced the expression of PC-1 and ANK in MLO-A5 cells. These molecules are known to regulate the accumulation of extracellular inorganic pyrophosphate and may affect the mineralization of the cells. Further studies are required to elucidate the regulatory mechanism of mineralization through Ras-Erk pathways.

In summary, we found that the Erk pathway is a negative regulator of skeletal mineralization both in vitro and in vivo. Therapeutics targeting Erk pathways can promote bone strength and bone quality by modulating matrix mineralization.

#### Acknowledgments

The authors thank R. Yamaguchi (Department of Orthopaedic Surgery, The University of Tokyo), who provided expert technical assistance. AxLacZ was kindly provided by Izumu Saito (Institute of Medicine, The University of Tokyo), AxMek<sup>CA</sup> and AxRas<sup>DN</sup> by Hideki Katagiri (Tohoku University) and AxRunx2 by Toshihisa Komori (Nagasaki University). This work was in part supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by Health Science research grants from the Ministry of Health and Welfare of Japan.

#### References

- [1] Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. *J Cell Biochem* 1994;55:287–99.

- [2] Aubin JE, Liu F, Malaval L, Gupta AK. Osteoblast and chondroblast differentiation. *Bone* 1995;17:77S–83S.
- [3] Berry JL, Davies M, Mee AP. Vitamin D metabolism, rickets, and osteomalacia. *Semin Musculoskelet Radiol* 2002;6:173–82.
- [4] Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: Conserved structure and molecular mechanism. *Nature* 1991;349:117–27.
- [5] Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. *Oncogene* 1998;17:1395–413.
- [6] Chaudhary LR, Avioli LV. Extracellular-signal regulated kinase signaling pathway mediates downregulation of type I procollagen gene expression by FGF-2, PDGF-BB, and okadaic acid in osteoblastic cells. *J Cell Biochem* 2000;76:354–9.
- [7] Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. *Osf2/Cbfa1*: A transcriptional activator of osteoblast differentiation. *Cell* 1997;89:747–54.
- [8] Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, et al. *Runx2* induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. *J Cell Biol* 2004;166:85–95.
- [9] Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. *Nature* 2003;423:349–55.
- [10] Higuchi C, Myoui A, Hashimoto N, Kuriyama K, Yoshioka K, Yoshikawa H, et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. *J Bone Miner Res* 2002;17:1785–94.
- [11] Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. *Biochem J* 1996;317(Pt 1):59–64.
- [12] Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. *Biochem J* 1994;300(Pt 3):723–8.
- [13] Jaiswal RK, Jaiswal N, Bruder SP, Mbalaviele G, Marshak DR, Pittenger MF. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. *J Biol Chem* 2000;275:9645–52.
- [14] Kato Y, Boskey A, Spevak L, Dallas M, Hori M, Bonewald LF. Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. *J Bone Miner Res* 2001;16:1622–33.
- [15] Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of *Cbfa1* results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* 1997;89:755–64.
- [16] Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Avioli LV, et al. *Erk* is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. *J Biol Chem* 2001;276:14443–50.
- [17] Lynch MP, Stein JL, Stein GS, Lian JB. The influence of type I collagen on the development and maintenance of the osteoblast phenotype in primary and passaged rat calvarial osteoblasts: modification of expression of genes supporting cell growth, adhesion, and extracellular matrix mineralization. *Exp Cell Res* 1995;216:35–45.
- [18] Mankin HJ. Rickets, osteomalacia, and renal osteodystrophy. An update. *Orthop Clin North Am* 1990;21:81–96.
- [19] Mikuni-Takagaki Y. Mechanical responses and signal transduction pathways in stretched osteocytes. *J Bone Miner Metab* 1999;17:57–60.
- [20] Miyazaki T, Katagiri H, Kangae Y, Takayanagi H, Sawada Y, Yamamoto A, et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. *J Cell Biol* 2000;148:333–42.
- [21] Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor *osterix* is required for osteoblast differentiation and bone formation. *Cell* 2002;108:17–29.
- [22] Nakayama K, Tamura Y, Suzawa M, Harada S, Fukumoto S, Kato M, et al. Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. *J Bone Miner Res* 2003;18:827–35.
- [23] Su B, Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. *Curr Opin Immunol* 1996;8:402–11.
- [24] Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. *J Cell Biol* 1983;96:191–8.
- [25] Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. *Cell* 1990;61:203–12.
- [26] Williams LT. Signal transduction by the platelet-derived growth factor receptor. *Science* 1989;243:1564–70.
- [27] Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and *Cbfa1*. *Endocr Rev* 2000;21:393–411.

Author's  
 Accepted Manuscript

ORIGINAL ARTICLE

Ayako Suematsu · Yasuhito Tajiri · Tomoki Nakashima  
Junko Taka · Sae Ochi · Hiromi Oda · Kozo Nakamura  
Sakae Tanaka · Hiroshi Takayanagi

## Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis

Received: October 13, 2006 / Accepted: October 18, 2006

**Abstract** Finding a means to ameliorate and prevent bone destruction is one of the urgent issues in the treatment of rheumatoid arthritis. Recent studies revealed bone-resorbing osteoclasts to be essential for arthritic bone destruction, but to date there has been scarce experimental evidence for the underlying mechanism of the bone-protective effect of antirheumatic drugs. Here we examined the effects of one or a combination of disease-modifying antirheumatic drugs (DMARDs) on osteoclast differentiation to provide a cellular and molecular basis for their efficacy against bone destruction. The effects on osteoclast precursor cells and osteoclastogenesis-supporting cells were distinguished by two *in vitro* osteoclast culture systems. Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF- $\kappa$ B ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1. MTX and SASP also suppressed RANKL expression on osteoclastogenesis-supporting mesenchymal cells. Interestingly, the combination of three antirheumatic drugs exerted a marked inhibitory effect on osteoclastogenesis even at a low dose at which there was much less of an effect when administered individually. These results are consistent with the reported efficacy of combined DMARDs therapy in humans and

suggest that osteoclast culture systems are useful tools to provide an experimental basis for the bone-protective effects of antirheumatic drugs.

**Key words** Disease-modifying antirheumatic drugs (DMARDs) · Nuclear factor of activated T cells (NFAT) c1 · Osteoclast · Receptor activator of NF- $\kappa$ B ligand (RANKL) · Rheumatoid arthritis (RA)

### Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterized by the chronic inflammation of synovial joints which results in severe bone destruction.<sup>1,2</sup> A number of anti-inflammatory and antirheumatic drugs have been clinically utilized in the treatment of RA, but there is no method to prevent bone destruction completely.<sup>3,4</sup> This is partly because all the antirheumatic drugs were originally developed to suppress the activation of the immune system.<sup>5</sup> However, a combined use of disease-modifying antirheumatic drugs (DMARDs) has considerably contributed to the amelioration of both inflammation and bone destruction, although the effects are still not fully satisfactory.<sup>6–8</sup> It is poorly understood how the antirheumatic drugs exert their bone-protective effects, and it has thus been extremely difficult to predict the efficacy of antirheumatic drugs against bone destruction based on *in vitro* experiments.

Osteoclasts are multinucleated cells of monocyte/macrophage lineage that resorb bone matrix.<sup>9,10</sup> The generation of osteoclasts is supported by mesenchymal cells such as osteoblasts, which provide signals essential for differentiation.<sup>11</sup> These signals are mediated by macrophage colony-stimulating factor (M-CSF), receptor activator of NF- $\kappa$ B ligand (RANKL), and costimulatory signals for RANKL.<sup>12–16</sup> For the evaluation of osteoclast formation, two types of *in vitro* osteoclast differentiation systems have been developed: osteoclast precursor cells, bone marrow-derived monocyte/macrophage lineage cells (BMMs), which are stimulated with recombinant RANKL and M-CSF (the

A. Suematsu · T. Nakashima · J. Taka · S. Ochi · H. Takayanagi (✉)  
Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University and COE Program for Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8549, Japan  
Tel. +81-3-5803-5471; Fax +81-3-5803-0192  
e-mail: taka.csi@tmd.ac.jp

Y. Tajiri · K. Nakamura · S. Tanaka  
Department of Orthopaedic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

H. Oda  
Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan


H. Takayanagi  
Solution-Oriented Research for Science and Technology (SORST), Japan Science and Technology Agency (JST), Kawaguchi, Japan


RANKL/M-CSF system, Fig. 1a), or are cocultured with osteoblasts in the presence of 1,25-(OH)<sub>2</sub> vitamin D<sub>3</sub> (VitD<sub>3</sub>) and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) (the coculture system, Fig. 2a). The RANKL/M-CSF system is suitable for looking at the direct effect of drugs on the osteoclast precursor cells and RANKL-induced signaling events.<sup>17,18</sup> The coculture system is useful in the investigation of the effect of drugs on the osteoclastogenesis-supporting cells and the expression of osteoclastogenic factors such as RANKL.<sup>19</sup>

Osteoclasts are abundantly observed at the bone/synovium interface in the joints of RA patients.<sup>2,20,21</sup> RANKL is highly expressed by synovial fibroblasts in arthritic joints and is responsible for the abnormal activation of osteoclasts.<sup>22,23</sup> Importantly, arthritic bone destruction is greatly reduced in *RANKL*<sup>-/-</sup> mice or *Fos*<sup>-/-</sup> mice, both of which lack osteoclasts, even though there is no significant difference in the level of inflammation between the wild type and these genetically modified mice.<sup>24,25</sup> Consistent with this, anti-osteoclast therapy has successfully ameliorated bone damage in models of inflammatory bone destruction.<sup>26-28</sup> Thus, accumulating evidence indicates that bone destruction in RA is attributable to the abnormal activation of osteoclasts and that inhibition of RANKL-mediated osteoclastogenesis may be an ideal method to control arthritic bone destruction.<sup>1,3,12</sup>

Methotrexate (MTX), a folate antagonist, is an antirheumatic drug widely used in the world, often in combination with other drugs such as salazosulphapyridine (SASP).<sup>6,7,29</sup> Bucillamine (Buc), *N*-(2-mercapto-2-methylpropionyl)-L-cysteine, is used clinically in Japan and Korea to treat patients with RA.<sup>30-32</sup> Buc has structural similarities to D-penicillamine, but contains two free sulfhydryl groups, resulting in molecular and therapeutic effects significantly different from D-penicillamine.<sup>32</sup> Here we examined the effect of MTX, Buc and SASP on the osteoclast differentiation using two mouse *in vitro* osteoclast formation systems and found that the three drugs exerted inhibitory effects on osteoclastogenesis by differentially acting on osteoclast precursor and osteoclastogenesis-supporting cells. Even though the effect of a low dose of the drugs administered individually was small, in combination they had a marked inhibitory effect on osteoclastogenesis through a downregulation of nuclear factor of activated T cells (NFAT) c1 induction. Thus, the analysis of the effect of antirheumatic drugs on *in vitro* osteoclast differentiation may provide a crucial clue on their capacity to protect against bone destruction.

**Fig. 1.** Effects of methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) on receptor activator of NF- $\kappa$ B ligand (RANKL)-induced osteoclastogenesis. **a** A schematic of the osteoclast formation system induced by RANKL and macrophage-colony stimulating factor (M-CSF) (the RANKL/M-CSF system). **b** Effects of MTX, Buc, and SASP on the cell number of osteoclast precursor cells. Bone marrow-derived monocyte/macrophage lineage cells (BMMs) were treated with MTX, Buc, or SASP in the presence of M-CSF. Four days later, the number of osteoclast precursor cells was estimated microscopically. **c** Effect of MTX, Buc, or SASP on osteoclastogenesis in the RANKL/M-CSF system. **d** Microscopic photographs of RANKL-induced osteoclastogenesis in the presence of MTX, Buc or SASP (TRAP staining). **e** Expression of *NFATc1* protein in RANKL-stimulated BMMs treated with MTX (10 nM), Buc (100  $\mu$ M) or SASP (60  $\mu$ M)





**Fig. 2.** Effect of methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) on osteoclastogenesis in the coculture system. **a** A schematic of the coculture system for osteoclastogenesis. BMCs, bone marrow cells; VitD<sub>3</sub>, 1,25-(OH)<sub>2</sub> vitamin D<sub>3</sub>; PGE<sub>2</sub>, prostaglandin E<sub>2</sub>. **b** Effects of MTX, Buc or SASP on osteoclastogenesis in the coculture system. **c** Microscopic photographs of osteoclastogenesis in the coculture in the presence of MTX, Buc, or SASP (TRAP staining). **d** Expression of *RANKL* mRNA in osteoblasts stimulated with Buc or SASP evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR). Mouse primary osteoblasts were stimulated with VitD<sub>3</sub> in the presence of Buc or SASP for 4 days. RT-PCR analysis was repeated several times and yielded similar results; a representative set of data is shown

## Materials and methods

### The RANKL/M-CSF system for in vitro osteoclast formation

The method of the RANKL/M-CSF system for osteoclastogenesis was described previously,<sup>17,33</sup> and is here utilized with modifications (see Fig. 1a). Nonadherent bone marrow cells (BMCs) were obtained from C57BL/6 mice (6- to 8-week-old) (CLEA Japan, Tokyo, Japan) maintained under specific pathogen-free conditions. All animal experiments were performed with the approval of the Animal Study Committee of Tokyo Medical and Dental University, and conformed to recognized guidelines and laws. BMCs were seeded ( $2 \times 10^5$  per well in a 24-well plate), and cultured in  $\alpha$ -MEM (Gibco, Paisly, UK) containing 10% fetal bovine serum (FBS; Sigma, St. Louis, MO, USA), 0.1  $\mu$ g/ml ampicillin, 0.1 mg/ml kanamycin (Meiji Seika, Tokyo, Japan) and 10 ng/ml recombinant M-CSF (R&D Systems, Minneapolis, MN, USA) for 2 days. Adherent cells were used as BMMs after washing out the nonadherent cells including lymphocytes. These BMMs were stimulated with 50 ng/ml recombinant RANKL (PeproTech, Rocky Hill, NJ, USA) in the presence of 10 ng/ml M-CSF for additional 3 days. The treatment of BMMs with MTX, Buc or SASP (Santen Pharmaceutical, Tokyo, Japan) started 1 day before RANKL treatment and continued until the end of the culture. The medium was replaced completely every 2 days. Tartrate-resistant acid phosphatase-positive multinucleated cells (TRAP<sup>+</sup> MNCs) (>3 nuclei unless otherwise indicated) were counted.

### The coculture system for in vitro osteoclast formation

The method of coculture system for osteoclastogenesis was described previously,<sup>14,34</sup> and utilized with modifications (see Fig. 2a). Primary osteoblasts were isolated from the calvaria of newborn (1–2 days old) mice by enzymatic digestion in  $\alpha$ -MEM medium with 0.1% collagenase (Wako, Osaka, Japan) and 0.2% dispase (Sanko Junyaku, Tokyo, Japan) and cultured in  $\alpha$ -MEM with 10% FBS. One day after these osteoblasts were reseeded ( $1 \times 10^4$  per well in a 24-well plate), BMCs ( $1 \times 10^5$  per well in a 24-well plate) were added to the culture of osteoblasts and cocultured in  $\alpha$ -MEM with 10% FBS containing  $1 \times 10^{-8}$  M VitD<sub>3</sub> and  $1 \times 10^{-6}$  M PGE<sub>2</sub> (Wako) for 7 days. One day after BMCs were added, MTX, Buc or SASP was added to the coculture. TRAP<sup>+</sup> MNCs (>3 nuclei) were counted 7 days after addition of BMC.

### Immunofluorescence staining

Cells were fixed in 4% paraformaldehyde/phosphate buffered saline (PBS) for 20 min, and treated with 0.2% Triton X-100 for 5 min. The cells were sequentially incubated in 5% bovine serum albumin/PBS for 30 min, 2  $\mu$ g/ml anti-NFATc1 monoclonal antibody (7A6, Santa Cruz Biotech-

nology, Santa Cruz, CA, USA) for 60 min and then in Alexa Fluor 488-labeled secondary antibody (Molecular Probes, Eugene, OR, USA) for 60 min. The relative expression of NFATc1 was calculated by computational densitometry using NIH Image software.

#### RNA extraction and reverse transcriptase-polymerase chain reaction analysis

Osteoblasts isolated from mouse calvaria were reseeded ( $1 \times 10^7$  per well in a 10-cm dish), and cultured in  $\alpha$ -MEM with 10% FBS containing  $1 \times 10^{-8}$  M VitD<sub>3</sub> in the presence of Buc (0–130  $\mu$ M) or SASP (0–75  $\mu$ M) for 4 days. Total RNA was extracted using ISOGEN (Nippon Gene, Tokyo, Japan) and first-strand complementary DNA (cDNA) was synthesized from total RNA using the One-Step RNA PCR kit (Takara Bio, Shiga, Japan) according to the manufacturer's protocol. The primers used for the mouse RANKL were the following: 5'-TCAGAAGACAGCACTCAGTG-3' (sense) and 5'-TCTTCACCAGCTCGGAGCTT-3' (antisense). The amplification protocol consisted of an initial denaturation at 94°C for 2 min, followed by 40 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 90 s. The level of mRNA expression was normalized with that of GAPDH expression. The PCR products were subjected to electrophoresis on 1.5% agarose gels and stained with ethidium bromide, and the bands were measured by computational densitometry using NIH Image software.

#### Statistical analysis

All data are expressed as mean  $\pm$  s.e.m ( $n = 5$ ). Statistical analysis was performed using Student's *t*-test or ANOVA followed by the Bonferroni test, if applicable ( $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ , unless otherwise indicated). Results are representative examples of three or more independent experiments.

## Results

The effect of antirheumatic drugs such as MTX and SASP on osteoclast formation have been described in previous reports.<sup>35</sup> However, these drugs have cell toxicity at high doses and it has been unclear whether the effects of these drugs have been investigated properly at concentrations that do not induce cell toxicity. Therefore, we first examined the effect of MTX, Buc, and SASP on the survival of osteoclast precursor cells, BMMs. BMMs were obtained by stimulating mouse BMCs with M-CSF, and the cell number of BMMs was counted after 4-day culture in the presence of various concentrations of MTX, Buc and SASP. All of these drugs had no effect on the cell number of BMMs at low concentrations, suggesting that they did not affect cell survival or proliferation. In contrast, they had severe toxic effects at high concentrations (Fig. 1b). Therefore, we used

concentrations of the drugs (MTX: 0.1–10 nM, Buc: 1–100  $\mu$ M, SASP: 3–60  $\mu$ M) at which they exerted minimal effects on the cell number of BMMs. When these drugs were added to the RANKL/M-CSF system at these concentrations (Fig. 1a), all three drugs had statistically significant but mild suppressive effects on osteoclast differentiation in a dose-dependent manner, as revealed by the decreased formation of TRAP<sup>+</sup> MNCs (Fig. 1c, d).

NFATc1 is the essential transcription factor for osteoclastogenesis.<sup>17,36</sup> It has been shown that RANKL dramatically induces the expression of NFATc1 through an autoamplification mechanism and the level of NFATc1 determines the fate of cells of the osteoclast lineage.<sup>36</sup> Certain antirheumatic drugs that have bone-protective effects inhibit osteoclastogenesis by suppressing RANKL-induced NFATc1 expression.<sup>17,20</sup> To analyze the effects of the three antirheumatic drugs on the expression of NFATc1, we quantitated the protein level of NFATc1 in the RANKL-stimulated BMMs after immunostaining with a specific antibody against NFATc1. All three drugs had similar inhibitory effects on NFATc1 induction, although the effects were only partial (Fig. 1e). These results suggest that the drugs inhibited osteoclast differentiation by interfering with RANKL signaling pathways upstream of NFATc1 induction.

We next examined the effects of MTX, Buc, and SASP on osteoclast differentiation in the coculture system with osteoblasts. In the coculture system, VitD<sub>3</sub> and PGE<sub>2</sub> are used to induce RANKL expression on the osteoblasts, and this system is useful in analyzing the effects of drugs on mesenchymal cells such as osteoblasts and synovial fibroblasts in addition to osteoclast precursor cells.<sup>22,35</sup> The same concentrations of MTX, Buc and SASP as in Fig. 1c were added to the coculture system (Fig. 2a). At these concentrations, there were no toxic effects of these drugs on the osteoblasts (data not shown). MTX and SASP exhibited greater inhibitory effects on the formation of TRAP<sup>+</sup> MNCs than in the RANKL/M-CSF system (Fig. 2b), suggesting that MTX and SASP exert anti-osteoclastogenic effects additionally through their effects on mesenchymal cells. In contrast, the inhibitory effects of Buc on the formation of TRAP<sup>+</sup> MNCs in the coculture system is similar to those in the RANKL/M-CSF system (Fig. 2b), suggesting that Buc mainly acts on osteoclast precursor cells to inhibit osteoclastogenesis. The photographs of TRAP<sup>+</sup> MNCs cultured in the presence of these drugs indicate that the size of the TRAP<sup>+</sup> MNCs was smaller than the non-treated cells and the number of nuclei per multinucleated cell was decreased in cells treated with the three drugs (Fig. 2c).

Consistent with the additional inhibitory effects of SASP and MTX on the coculture system in comparison with the RANKL/M-CSF system, it has been reported that both SASP and MTX have an inhibitory effect on RANKL expression in synovial cells.<sup>35</sup> However, it remains unknown how Buc acts on the expression of RANKL on the osteoclastogenesis-supporting cells. Therefore, we evaluated mRNA expression of RANKL in the osteoblasts stimulated with VitD<sub>3</sub> and PGE<sub>2</sub> in the presence of Buc in comparison with SASP. As expected, SASP strongly inhib-


ited the mRNA expression of RANKL on osteoblasts, but Buc had only minimal effects on RANKL expression (Fig. 2d). This result further supports the notion that Buc mainly targets osteoclast precursor cells in terms of its inhibitory effect on osteoclastogenesis. Thus, antirheumatic drugs affect osteoclastogenesis through different target cells.

To gain mechanistic insight into the efficacy obtained with the combined use of antirheumatic drugs in the treatment of RA, we evaluated the effects of a combination of MTX, Buc and SASP on osteoclast differentiation in the RANKL/M-CSF system. The addition of a low dose of MTX alone had a limited suppressive effect on osteoclastogenesis, but a combined addition with Buc or SASP increased the inhibitory effects (Fig. 3a, b). The combined use of all three drugs had a marked inhibitory effect on osteoclastogenesis, even though the addition of individual drugs at the same concentration had only a slight effect (Fig. 3a, b).

In addition, we quantitated the protein level of NFATc1 in the RANKL-stimulated BMMs after immunostaining, and this revealed that RANKL-induced NFATc1 expression was significantly inhibited by treatment with a combination of the three drugs (Fig. 3c), although treatment with individual drugs at the same concentration had only a small effect on NFATc1 expression (Fig. 1e). Interestingly, the photograph of TRAP<sup>+</sup> MNCs showed that the multinucleation was severely impaired in the cells treated with a combination of the three drugs (Fig. 3b). Therefore, we investigated the number of TRAP<sup>+</sup> MNCs containing more than 20 nuclei. We found that the number of such large osteoclasts was dramatically suppressed by the combined addition of the three antirheumatic drugs (Fig. 3d). It is worth noting that even a very low dose of MTX (0.1 nM) in combination with Buc and SASP exerted a much more suppressive effect than an addition of the same concentration of MTX alone (Fig. 3d). These results suggest that the combination with other antirheumatic drugs contributes to the enhancement of the inhibitory effect of MTX in terms of differentiation into large osteoclasts with numerous nuclei.

## Discussion


It has long been a challenging question as to how abnormalities of the immune system induce bone damage in RA.<sup>1,2,37</sup> Although the observation of giant cells at the bone destruction site dates back to about two decades ago,<sup>38</sup> osteoclasts have not been placed at the center of the pathogenesis of RA. After RANKL was cloned and the high RANKL expression in the synovium was brought to light, the importance of bone-resorbing osteoclasts gained general acceptance.<sup>3,12</sup> RANKL is abundantly expressed by RA synovial fibroblasts, possibly due to stimulation with proinflammatory cytokines.<sup>18,22,39</sup> In addition, RANKL is expressed in activated T cells,<sup>27</sup> although the effects of T cells on osteoclastogenesis are counterbalanced by negative factors such as IFN- $\gamma$ .<sup>33</sup>



**Fig. 3.** Effects of methotrexate (MTX) alone or with the combined addition of bucillamine (Buc) and/or salazosulphapyridine (SASP) on osteoclastogenesis in the RANKL/M-CSF system. **a** Effects of MTX alone or MTX plus Buc (10  $\mu$ M) and/or SASP (30  $\mu$ M) on RANKL-induced osteoclastogenesis. <sup>#</sup> $P < 0.05$ , <sup>##</sup> $P < 0.05$ , <sup>###</sup> $P < 0.001$  versus untreated BMMs. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  versus MTX-treated BMMs. # $P < 0.01$  versus MTX/Buc-treated BMMs. <sup>†</sup> $P < 0.05$  versus MTX/SASP-treated BMMs. **b** Microscopic photographs of RANKL-induced osteoclastogenesis in cells treated with MTX alone or MTX plus Buc and/or SASP (TRAP staining). **c** Expression of NFATc1 protein in RANKL-stimulated BMMs treated with a combination of MTX (10 nM), Buc (10  $\mu$ M) and SASP (30  $\mu$ M). **d** Effect of the combined addition of MTX, Buc, and SASP on the formation of TRAP<sup>+</sup> MNCs containing more than 20 nuclei. Statistical analysis was performed in comparison with MTX-treated cells

How is T cell activation linked to the enhanced expression of RANKL in RA? A recent study in our laboratory revealed that interleukin (IL)-17-producing helper T (Th) 17 cells play a distinct role in the pathogenesis of autoimmune arthritis and promote osteoclastogenesis, mostly through the production of IL-17.<sup>37</sup> As summarized in Fig. 4,





**Fig. 4.** How antirheumatic drugs, including methotrexate (MTX), buccillamine (Buc) and salazosulphapyridine (SASP) inhibit the pathways promoting bone destruction in rheumatoid arthritis (RA). Among the T-cell-derived mediators of inflammation, interleukin (IL)-17 has emerged as one of the most important factors in the pathogenesis of RA. IL-17 not only induces RANKL on osteoblasts/synovial fibroblasts of mesenchymal origin, but also activates local inflammation, leading to the upregulation of inflammatory cytokines such as TNF- $\alpha$  and IL-1. These cytokines also induce RANKL on mesenchymal cells and additionally act directly on the osteoclast precursor cells to greatly enhance the RANKL activity. RANKL activates the differentiation of osteoclasts by inducing the expression of *NFATc1*, the master transcription factor for osteoclastogenesis. In this study, we showed that MTX, Buc and SASP suppress RANKL-induced *NFATc1* expression, and that MTX and SASP inhibit RANKL expression on mesenchymal cells (shown in boxes). It has been previously reported that these three drugs exert inhibitory effects on the activation of T cells and inflammatory responses of synovial cells (shown in the left lower section)

IL-17 induces RANKL on mesenchymal cells (synovial fibroblasts/osteoblasts) and also stimulates local inflammation by inducing proinflammatory cytokines such as IL-1 and TNF- $\alpha$ , which in turn induces RANKL expression on mesenchymal cells.<sup>3,40</sup> RANKL then acts on osteoclast precursor cells of monocyte/macrophage lineage and stimulates osteoclast differentiation via the induction of *NFATc1*.<sup>17,36</sup>

This study demonstrates the mechanisms underlying the bone-protective effects of antirheumatic drugs (summarized in Fig. 4): MTX, Buc, and SASP had a suppressive effect on osteoclast differentiation by acting on osteoclast precursor cells and inhibiting RANKL-mediated expression of *NFATc1* on the one hand. On the other hand, MTX and SASP had inhibitory effects on the RANKL expression in mesenchymal cells. It has been reported that MTX, Buc, and SASP inhibit the activation of T cells and inflammatory responses of synovial cells (which is also indicated in Fig. 4).<sup>29,41–43</sup> This may explain the anti-inflammatory effects of these drugs, but does not provide insight into how these drugs are related to the regulation of bone cells, which question we addressed experimentally in this study.

In keeping with the observation that the administration of these drugs individually has only limited clinical efficacy against bone destruction,<sup>3,44</sup> they have only a small inhibitory effect on osteoclast differentiation. However, such in vitro inhibitory effects is enhanced if the drugs are administered in combination. This is consistent with the efficacy of combined DMARDs therapy in comparison with the treatment with a single DMARD.<sup>6,7,31</sup> It was recently reported that the combination of MTX and Buc has more beneficial effects than MTX alone in treating RA patients.<sup>45</sup>

It is likely that a combination of antirheumatic drugs that inhibit osteoclastogenesis through different mechanisms will be helpful in ameliorating or preventing bone destruction in RA.

There are a number of drugs available for the treatment for RA, but most of them were developed to modulate immune reactions.<sup>15</sup> Therefore, antirheumatic drugs, effective in treating pain and inflammation, do not always have bone-protective effects: patients still fairly frequently have to undergo joint replacement surgery because of the progressive bone damage that develops despite treatment with antirheumatic drugs.<sup>3,46</sup> This study provides a beneficial method to screen antirheumatic drugs for their efficacy against bone destruction. Despite the remarkable impact of anti-cytokine therapies on the treatment of RA,<sup>47</sup> it scarcely needs saying that antirheumatic drugs will continue to occupy a substantially important position in the foreseeable future.<sup>5,8</sup> The mechanism of action of antirheumatic drugs in the context of bone destruction has been poorly understood, but the identification of an effective set of existing antirheumatic drugs by means of in vitro osteoclast culture systems is a promising strategy for improving the future treatment of RA.

**Acknowledgments** We thank Santen Pharmaceutical Co., Ltd. and H. Aono for providing reagents and technical advice. We also thank K. Sato, H.J. Gober, T. Koga, and I. Takayanagi for fruitful discussion and assistance. This work was supported in part by Grant-in-Aid for Creative Scientific Research from the Japan Society for the Promotion of Science (JSPS), SORST program of JST, grants for Genome Network Project from Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT), grants for the 21st Century COE program from MEXT, Grants-in-Aid for Scientific Research from MEXT, Health Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan, and grants from the Naito Foundation, Suzuken Memorial Foundation, Uehara Memorial Foundation, Kato Memorial Bioscience Foundation, Cell Science Research Foundation, the Ichiro Kanehara Foundation, Inamori Foundation and the Nakatomi Foundation. The authors declare no competing financial interests.

## References

1. Takayanagi H. Osteoimmunological insight into bone damage in rheumatoid arthritis. *Mod Rheumatol* 2005;15:225–31.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. *Nature* 2003;423:356–61.
3. Sato K, Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. *Curr Opin Rheumatol* 2006;18:419–26.
4. Takayanagi H. Inflammatory bone destruction and osteoimmunology. *J Periodontol Res* 2005;40:287–93.
5. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. *Nat Rev Drug Discov* 2003;2:473–88.
6. Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B, et al. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. *Ann Rheum Dis* 2006;65:45–50.
7. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schatzenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. *Ann Rheum Dis* 1999;58:220–5.
8. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in

- patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;363:675–81.
9. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. *Nat Rev Genet* 2003;4(8):638–49.
  10. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003;423:337–42.
  11. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. *Endocr Rev* 1999;20:345–57.
  12. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. *Annu Rev Immunol* 2002;20:795–823.
  13. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. *J Mol Med* 2005;83:170–9.
  14. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. *Nature* 2004;428:758–63.
  15. Ross FP, Teitelbaum SL. Alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. *Immunol Rev* 2005;208:88–105.
  16. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. *Annu Rev Immunol* 2006;24:33–63.
  17. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. *Dev Cell* 2002;3:889–901.
  18. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinoshita M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA* 1998;95:3597–602.
  19. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, et al. Osteoblastic cells are involved in osteoclast formation. *Endocrinology* 1988;123:2600–2.
  20. Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF- $\kappa$ B ligand-stimulated induction of nuclear factor of activated T cells c1. *Arthritis Rheum* 2004;50:794–804.
  21. Gravalles EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. *Arthritis Rheum* 2000;43:2143–51.
  22. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor  $\kappa$ B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. *Arthritis Rheum* 2000;43:259–69.
  23. Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T, et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. *Biochem Biophys Res Commun* 1997;240:279–86.
  24. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. *Am J Pathol* 2001;159:1689–99.
  25. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF- $\alpha$ -mediated joint destruction. *J Clin Invest* 2002;110:1419–27.
  26. Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T, Isshiki M, et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. *J Clin Invest* 1999;104:137–46.
  27. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. *Nature* 1999;402:304–9.
  28. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. *J Clin Invest* 2000;105:1697–710.
  29. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. *Arthritis Rheum* 2006;54:1366–77.
  30. Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. *Mod Rheumatol* 2006;16:85–91.
  31. Nagashima M, Shu G, Yamamoto K, Yamahata S, Yoshino S. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. epidemiology of DMARDs treatment in Japan. *Clin Exp Rheumatol* 2005;23:27–35.
  32. Tsuji F, Aono H, Okamoto M, Sasano M. Bucillamine, A unique anti-rheumatic drug. *Curr Top Pharmacol* [in press].
  33. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN- $\gamma$ . *Nature* 2000;408:600–5.
  34. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugge B, Nakashima K, et al. NFAT and Osterix cooperatively regulate bone formation. *Nat Med* 2005;11:880–5.
  35. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and anti-inflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor  $\kappa$ B, osteoprotegerin, and receptor activator of nuclear factor  $\kappa$ B ligand. *Arthritis Rheum* 2004;50:3831–43.
  36. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. *J Exp Med* 2005;202:1261–9.
  37. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. *J Exp Med* 2006;203:2673–82.
  38. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. *Arthritis Rheum* 1984;27:968–75.
  39. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. *Nat Clin Pract Rheumatol* 2005;1:47–54.
  40. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. *Nat Rev Immunol* 2006;6:329–33.
  41. Munakata Y, Iwata S, Dobers J, Ishii T, Nori M, Tanaka H, et al. Novel in vitro effects of bucillamine: inhibitory effects on proinflammatory cytokine production and transendothelial migration of T cells. *Arthritis Rheum* 2000;43:1616–23.
  42. Aono H, Hasunuma T, Fujisawa K, Nakajima T, Yamamoto K, Mita S, et al. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. *J Rheumatol* 1996;23:65–70.
  43. Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor  $\kappa$ B and induction of apoptosis in T-lymphocytes by sulfasalazine. *Br J Pharmacol* 1999;128:1361–9.
  44. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. *Ann Rheum Dis* 2004;63:149–55.
  45. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. *Mod Rheumatol* 2005;15:323–8.
  46. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med* 2001;344:907–16.
  47. Feldmann M, Maini RN. Anti-TNF $\alpha$  therapy of rheumatoid arthritis: what have we learned? *Annu Rev Immunol* 2001;19:163–96.

# Overexpression of $\gamma$ -Glutamyltransferase in Transgenic Mice Accelerates Bone Resorption and Causes Osteoporosis

Kiyoshi Hiramatsu, Yutaro Asaba, Sunao Takeshita, Yuji Nimura, Sawako Tatsumi, Nobuyoshi Katagiri, Shumpei Niida, Toshihiro Nakajima, Sakae Tanaka, Masako Ito, Gerard Karsenty, and Kyoji Ikeda

Department of Bone and Joint Disease (K.H., Y.A., S.Tak., S.Tat., N.K., S.N., K.I.) Research Institute, National Center for Geriatrics and Gerontology (NCGG), Obu, Aichi 474-8522, Japan; Department of Surgery (K.H., Y.A., Y.N.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; National Institute of Biomedical Innovation (S.Tat.), Osaka 567-0085, Japan; Department of Genome Science (T.N.), Institute of Medical Science, St. Marianna University of Medicine, Kanagawa 216-8512, Japan; Department of Orthopedic Surgery (S.Tan.), University of Tokyo School of Medicine, Tokyo 113-8655, Japan; Department of Radiology (M.I.), Nagasaki University School of Medicine, Nagasaki 852-8501, Japan; and Department of Genetics and Development (G.K.), Columbia University, New York, New York 10032

We previously identified  $\gamma$ -glutamyltransferase (GGT) by expression cloning as a factor inducing osteoclast formation *in vitro*. To examine its pathogenic role *in vivo*, we generated transgenic mice that overexpressed GGT in a tissue-specific manner utilizing the Cre-loxP recombination system. Systemic as well as local production of GGT accelerated osteoclast development and bone resorption *in vivo* by increasing the sensitivity of bone marrow macrophages to receptor activator of nuclear factor- $\kappa$ B ligand, an essential cytokine for osteoclastogenesis. Mutated GGT devoid of enzyme activity

was as potent as the wild-type molecule in inducing osteoclast formation, suggesting that GGT acts not as an enzyme but as a cytokine. Recombinant GGT protein increased receptor activator of nuclear factor- $\kappa$ B ligand expression in marrow stromal cells and also stimulated osteoclastogenesis from bone marrow macrophages at lower concentrations. Thus, GGT is implicated as being involved in diseases characterized by accelerated osteoclast development and bone destruction and provides a new target for therapeutic intervention. (*Endocrinology* 148: 2708–2715, 2007)

**A**GE-RELATED DISORDERS of the skeletal system are a major health problem worldwide (1, 2), and osteoclast bone resorption plays a central role in the pathogenesis of bone and joint diseases, such as osteoporosis and rheumatoid arthritis (3). Osteoclasts are multinucleate, giant cells derived from hematopoietic progenitor cells of monocyte-macrophage lineage and are the only cell type that resorbs bone to maintain skeletal integrity and calcium homeostasis (4). The dysregulated generation of osteoclasts with resultant elevation of bone resorption that takes place after menopause and with aging or as an immune/inflammatory response leads to osteoporotic fractures and the joint destruction associated with rheumatoid arthritis (5). Genetic studies on human patients as well as mutant mice have disclosed critical molecules involved in osteoclast development, including cytokines, intracellular signaling molecules, and nuclear transcription factors (3, 4). Among these, the osteoclastogenic cytokines have received special attention, because they represent novel targets for the development of both diagnostic tools and antiresorptive drugs (6). For ex-

ample, receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), belonging to the TNF family (6), was identified as an essential cytokine for osteoclastogenesis, and mice deficient in RANKL were found to lack osteoclasts completely and to exhibit severe osteopetrosis (7).

In an attempt to identify new cytokines that stimulate osteoclast differentiation, we employed an expression cloning strategy, where cRNA from T lymphoma cells known to possess high bone resorption activity was injected into *Xenopus* oocytes (8). By assaying the conditioned medium for osteoclastogenic activity in murine marrow cultures, we identified  $\gamma$ -glutamyltransferase (GGT) as such a stimulator (9). GGT is an ectopeptidase that catalyzes the transfer of a  $\gamma$ -glutamyl moiety to an acceptor and plays a critical role in glutathione degradation and cysteine metabolism (10, 11). Mice deficient in GGT exhibit growth retardation, cataracts, and severe osteoporosis and die at 10–18 wk of age (12, 13). We have found that purified GGT from rat kidney is capable of inducing osteoclast formation in bone marrow cultures *in vitro* (9), which raises the possibility that its excess may also be involved in the bone and joint pathology characterized by enhanced osteoclastic bone resorption. The transgenic mice obtained by the Cre-loxP recombination system in the present study produce GGT systemically as well as locally, demonstrating that GGT indeed contributes to bone destruction, independently of its enzymatic activity, by acting as a local cytokine.

First Published Online March 15, 2007

Abbreviations: CT, Computed tomography; DPD, deoxy pyridinoline; eGFP, enhanced green fluorescent protein; KO, knockout; M-CSF, macrophage colony-stimulating factor; pmtGGT, point-mutated GGT; RANKL, receptor activator of nuclear factor- $\kappa$ B ligand; TRAP, tartrate-resistant acid phosphatase.

*Endocrinology* is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

## Materials and Methods

### Reagents

Mouse macrophage colony-stimulating factor (M-CSF) and soluble RANKL were purchased from R&D Systems (Minneapolis, MN). Rabbit polyclonal anti-GGT antibody was a generous gift from Dr. N. Taniguchi (Osaka University, Osaka, Japan).

### Generation of transgenic mice and animal experiments

A transgenic cassette (floxed eGFP-GGT) carrying a CAG promoter and an enhanced green fluorescent protein (eGFP) flanked by loxP sites fused to mouse GGT cDNA with a polyadenylation signal was constructed. Mouse GGT cDNA was synthesized from RNA extracted from the kidney of C57BL/6 mouse, and Kozac sequences and *MfeI* restriction sites were added by using a primer set (5'-CCGCAATTGCCACCATGAAGAATCGGTTTCTGGTGC-3' and 5'-CCGCAATTGTCAGTAGC-CAGCAGGTTCCCGCC-3'). This GGT cDNA fragment was inserted into *EcoRI*-digested pCXP/loxGFP, which contained CAG promoter and eGFP (14). The transgenic construct was excised with *SalI* and *HindIII* endonucleases and purified by using standard techniques.

Founder floxed eGFP-GGT mice were generated by microinjection of the DNA into fertilized eggs of C57BL/6 mice. Integration of the transgene was identified by green fluorescence and confirmed by Southern and PCR analyses of genomic DNA extracted from the tail, by using the following primers: 5'-GGTGTCTGCCGCCAAGG-GAAGG-3' and 5'-GAGACACATCGACAAACTTTGGG-3' for GGT and 5'-TGAACCGCATCGAGCTGAAGGG-3' and 5'-TCCAGCAG-GACCATGTGATCGC-3' for eGFP. Floxed eGFP-GGT mice were crossed with CAG-Cre (15), RANKL knockout (KO) (7), and Col I-Cre (16) mice, to generate GGT-Tg, GGT-Tg/RANKL KO, and Col I-GGT mice, respectively.

Mice were raised under standard laboratory conditions at  $24 \pm 2$  C and 50–60% humidity and allowed free access to tap water and commercial standard rodent chow (CE-2) containing 1.20% calcium, 1.08% phosphate, and 240 IU/100 g vitamin D<sub>3</sub> (Clea Japan Inc., Tokyo, Japan). Both male and female mice were analyzed at the age of 9 wk. Urine was collected during the final 24 h, and blood samples were centrifuged to obtain the serum.

All experiments were performed in accordance with NCGG's ethical guidelines for animal care, and the experimental protocols were approved by the animal care committee.

### Bone and histological analyses

For bone analysis, right tibiae were dissected and stored in 70% ethanol for microcomputed tomography (micro-CT) scanning. Left tibiae were fixed in 4% paraformaldehyde, and bone histomorphometry was performed on un-decalcified sections, with tetracycline and calcein double labeling, as described previously (17). Histomorphometric parameters were measured at Niigata Bone Science Institute (Niigata, Japan).

Micro-CT scanning was performed on proximal tibiae by using a  $\mu$ CT-40 (SCANCO Medical AZ, Bassersdorf, Switzerland) with a resolution of 12  $\mu$ m, and microstructure parameters were calculated three-dimensionally as described previously (18).

### Biochemistry

Serum and urinary calcium, phosphate, creatinine, and GGT concentrations were determined by an autoanalyzer (Hitachi 7170, Tokyo, Japan). Urinary deoxyypyridinoline (DPD) was measured with a Pylinks-D assay kit (Metra Biosystems Inc., Santa Clara, CA). Tissue GGT activity was determined using a  $\gamma$ -GTP C-TestWako kit (Wako Pure Chemical Industries Ltd., Osaka, Japan) with L- $\gamma$ -glutamyl-p-N-ethyl-N-hydroxyethylaminoanilide as the substrate and glycylglycine as the acceptor, as described earlier (19).

### Cell cultures and osteoclastogenesis assay in vitro

HEK293 cells were transfected with the transgenic cassette (floxed eGFP-GGT) described above, with or without Cre recombinase, to confirm that the DNA construct functioned as designed.

Bone marrow cells were isolated from the tibiae and femurs of 6- to 9-wk-old male C57BL/6J mice (SLC, Shizuoka, Japan), and osteoclastogenesis assays were performed as described previously (20). In brief, bone marrow cells were plated in culture dishes containing  $\alpha$ -MEM, 10% heat-inactivated fetal bovine serum, antibiotics, and 1/10 volume of CMG14–12 culture supernatant (as a source of M-CSF). After 3 d culture, adherent cells were used as osteoclast precursor cells. Cells were then cultured with M-CSF (50 ng/ml) and soluble RANKL (50 ng/ml) for 4 d, fixed in 4% paraformaldehyde, and stained for tartrate-resistant acid phosphatase (TRAP). In some experiments, recombinant GGT was added at various concentrations to the culture. The number of multinucleate (at least three nuclei), TRAP-positive cells was counted as osteoclasts. Pit assay was performed on dentin slices as previously described (20), and analysis of pit area was performed on a Macintosh computer using the public domain NIH Image program (developed at the United States National Institutes of Health and available on the internet at <http://rsb.info.nih.gov/ni-image/>).

### Expression and purification of recombinant GGT

Recombinant GGT protein was generated using the baculovirus/insect cell system as described previously (21). In brief, human GGT cDNA in a pKBLgp64 vector (Oriental Yeast Co., Ltd, Tokyo, Japan) was cotransfected with DHBac10 (Invitrogen, San Diego, CA) using Cellfectin (Invitrogen) into Sf9 cells, which were then infected by the recombinant viruses. Cells were harvested, and the protein was extracted with 10 mM sodium phosphate buffer (pH 6.5)/1% Triton X-100 and further solubilized by protease treatment. The solubilized protein was purified through a hydroxylapatite column and isoelectric chromatography using PBE 94 (Pharmacia, Piscataway, NJ) and Polybuffer 74. The eluate was passed through a Sephacryl S-200 HR (Pharmacia) gel filtration column to remove the Polybuffer.

### Site-directed mutagenesis of GGT and retroviral expression

Serine residues at 451 and 452 of mouse GGT were replaced by alanine by site-directed mutagenesis using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. In brief, oligonucleotide primers containing mutations (5'-GGTAAGCAGCCTCTTGCAGCCATGTGTCCTCAATC-3' and 5'-GATTGAGGGACACATGGCTGCAAGAGGCTGCTTACC-3') were annealed to template DNA, and the mutant strand was synthesized and amplified by using *PfuTurbo* DNA polymerase (at 95 C for 30 sec, 55 C for 1 min, and 68 C for 5 min for 18 cycles). After the reaction products were treated with *DpnI* endonuclease, the mutated DNA was transformed into XL 10-Gold ultracompetent cells. Plasmid DNA was prepared from the transformants, and the mutated sequences were confirmed.

Retroviral vectors encoding wild-type and mutated GGT were used to transfect the retrovirus packaging cells, Plat-E (a gift from Dr. T. Kitamura, University of Tokyo) or GP2-293 (Clontech Laboratories, Inc., Palo Alto, CA). Osteoclast precursor cells were exposed to the retrovirus in the presence of polybrene (4  $\mu$ g/ml) and M-CSF for 1 d and were subsequently treated with RANKL and M-CSF for 4 d in the presence of puromycin (1.6  $\mu$ g/ml). Osteoclast differentiation was evaluated as described above. The retrovirus was also infected to primary osteoblasts isolated from newborn mouse calvaria, and alkaline phosphatase activity was assessed.

### Northern and RT-PCR analyses

Total RNA was isolated with TRIzol Reagent (Invitrogen), and equal amounts (10  $\mu$ g/lane) were fractionated on a 1.5% agarose gel. The specific mRNAs were detected by hybridization of Hybond N+ nylon membranes (Amersham Biosciences, Inc., Piscataway, NJ) with <sup>32</sup>P-labeled cDNA probes. For quantitative RT-PCR, total RNA (1  $\mu$ g) was reverse transcribed by using Superscript III (Invitrogen), and samples were analyzed using a Light Cycler system (Roche Diagnostics, Basel, Switzerland). The primers included 5'-CCCCTGCTGATTCATCTT-3' and 5'-GCATAGGCAACCGAAAGG-3' for GGT, 5'-TGAAGGCTCATGGTTGGAT-3' and 5'-CATTGATGGTGAG-TGTGCAA-3' for RANKL, 5'-GCTGCTACCCTGGAACCTC-3' and 5'-TGTGCACACCGTATCCTTGT-3' for RANK, 5'-ACCTGTCGTGAAACA-CACCA-3' and 5'-CTCAGACTGTCTTCAAGGC-3' for *c-fos*, 5'-

GCAAAGATGGAAACGACCTTCTAC-3', 5'-GGCCAGGTTCAAGGTCA T  
 GCCTCT-3' for *c-jun*, 5'-TGCAAGCGCTCACCGTCTAC-3', 5'-ACCGACA-  
 GATACTGCTCGCAAA-3' for NFATc1, and 5'-TGCTGCCATTGTT-  
 GATATGG-3' and 5'-TCCACAGCTTTGATGACACC-3' for EF-1 $\alpha$ . The  
 amount of target mRNA was corrected by that of EF-1 $\alpha$  mRNA.

#### Western blot analysis

Cells were lysed in the buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM  $\beta$ -glycerophosphate, 1 mM Na<sub>3</sub>VP<sub>4</sub>, 1 mM NaF, and 1 $\times$  protease inhibitor mixture. Cell lysates were boiled in the presence of SDS sample buffer [0.5 M Tris-HCl (pH 6.8), 10% glycerol, and 0.05% (wt/vol) bromophenol blue] for 5 min and subjected to electrophoresis on 10% SDS-PAGE. Proteins were transferred to Hybond-C extra nitrocellulose membranes from Amersham using a semidry blotter and incubated in blocking solution (5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween 20) for 1 h to reduce nonspecific binding. Membranes were then exposed to anti-GGT antibody overnight at 4 C, washed three times, and incubated with goat antirabbit IgG horseradish peroxidase-conjugated antibody for 1 h. Membranes were washed extensively, and enhanced chemiluminescence detection assay was performed according to the manufacturer's instructions.

#### Statistical analysis

Data are expressed as the mean  $\pm$  sd. Statistical analysis was performed by Student's *t* test. Values were considered statistically significant at *P* < 0.05.

### Results

#### Generation of GGT transgenic mouse

To test whether GGT could induce osteoclast formation and stimulate bone resorption *in vivo*, we used the Cre-loxP recombination system to generate transgenic mice that produced GGT systemically or locally. As schematically illustrated in Fig. 1A, we constructed a transgenic cassette that carries floxed eGFP fused to mouse GGT cDNA with a polyadenylation signal, under the control of the chicken  $\beta$ -actin (CAG) promoter driving ubiquitous gene expression. When HEK293 cells were transfected with this DNA construct, green fluorescence was observed (Fig. 1B) with little GGT activity in conditioned medium or cellular extracts (Fig. 1C). Upon the introduction of Cre recombinase, GGT activity as well as its mRNA was markedly induced (Fig. 1C), whereas the green fluorescence gradually weakened (Fig. 1B), indicating that the DNA cassette functioned as designed.

Nine transgenic founders were produced using the standard pronuclear injection protocol. Floxed eGFP-GGT mice were identified by their green color (Fig. 1D), and their genotype was confirmed by the presence of the GGT transgene in genomic DNA extracted from their tails (Fig. 1E) and by Southern hybridization (data not shown). Floxed eGFP-GGT male mice were then mated to female CAG-Cre transgenic mice to generate transgenic lines that produced GGT systemically. Of the four independent transgenic founders (GGT-Tg lines) obtained, two (A and B) were found to have lost the Cre gene and therefore were propagated for further investigation by mating to C57BL/6 wild-type females, because their progeny allowed avoidance of deleterious effects due to the presence of the Cre gene. Pups of both lines were born at the expected ratio, appeared normal, grew indistinguishably from wild-type mice, and were fertile. The two lines (A and B) displayed a very similar phenotype, and the results presented are from GGT-Tg line A.





Fig. 1. Generation of floxed eGFP-GGT transgenic mice. A, Schematic representation of the transgenic construct (floxed eGFP-GGT). eGFP flanked by loxP sites fused to mouse GGT cDNA was placed under the control of a CAG promoter. Arrows indicate a set of primers used for confirming integration of the transgene. B and C, GFP expression in HEK293 cells transfected with the floxed eGFP-GGT construct without and with Cre recombinase transfection. Green fluorescence gradually decreased after introduction of the Cre gene (B), whereas the content of GGT mRNA and the activity of the enzyme in the culture supernatant were markedly induced after expression of Cre recombinase (C). D and E, Floxed GFP-GGT mice were identified by green color (D), and transgene expression was confirmed by PCR with the primer set shown in A (E). WT, Wild type.

Northern blot analysis of RNAs extracted from various tissues revealed that GGT mRNA was expressed predominantly in the kidney of the wild-type mouse, whereas it was found in a variety of tissues, including bone and bone marrow, in the GGT-Tg mouse (Fig. 2A). Production of actual GGT protein was also confirmed by measuring its enzymatic activity. In agreement with the mRNA tissue distribution, GGT enzymatic activity was highest in the kidney of wild-type mice, whereas the GGT-Tg mouse exhibited high enzyme activity in various tissues in addition to the kidney (Fig. 2B).

#### Systemic overexpression of GGT accelerates bone resorption and induces osteopenia with microstructural deterioration

GGT-Tg mice grew normally, and their body weight was indistinguishable from wild-type littermates (Fig. 2C). The data presented here are based on the analysis of 9-wk-old

FIG. 2. Identification of GGT-Tg mice with increased GGT production. A, Tissue distribution of GGT mRNA by Northern blot analysis in various tissues from GGT-Tg mice and wild-type (WT) littermates. EF-1 $\alpha$  mRNA was used as control for loading. B, GGT enzymatic activities (in IU/wet tissue weight) were determined in various tissues from GGT transgenic (Tg) mice and wild-type (WT) littermates. \*,  $P < 0.05$  ( $n = 3$  in each group). C, Body weight of wild-type (WT) and GGT transgenic (Tg) mice. No difference was observed;  $n = 8$  for each group. D, Serum GGT activity and urinary DPD excretion. Urinary DPD was corrected for creatinine (Cr). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  vs. WT ( $n = 8$  for each group).



male mice, but a similar phenotype was observed in female mice. GGT-Tg mice exhibited a high serum concentration of GGT and significantly higher urinary excretion of DPD, a biochemical marker of bone resorption, compared with wild-type mice (Fig. 2D).

The effects of GGT overexpression on trabecular bone structure in GGT-Tg mice were analyzed by micro-CT scanning of the tibial metaphysis. As shown in Fig. 3, micro-CT images of

the trabecular compartment of the proximal tibia reveal marked osteopenia with a substantial reduction in the three-dimensional-bone volume fraction (BV/TV). Microstructural analysis revealed the bone of GGT-Tg mice to be characterized by significant decreases in connectivity and trabecular thickness and number and by increases in trabecular separation and structure model index (Fig. 3B), indicating the trabeculae of GGT-Tg mice had become thinned, less connected, and converted from its normal plate-like structure to a more fragile, rod-like structure.

The effects of GGT excess on bone remodeling were further analyzed by histomorphometry at the proximal tibia. As shown in Fig. 4, as histological indices of bone resorption, the number of osteoclasts (N.Oc/BS), the bone surface covered by osteoclasts (Oc.S/BS), and the eroded surface (ES/BS), were all significantly elevated in GGT-Tg mice compared with the wild-




FIG. 3. GGT-Tg mice exhibit osteopenia with microstructural deterioration. A, Representative three-dimensional images obtained by micro-CT of trabecular bone at the tibiae of wild-type (WT) and of GGT transgenic (Tg) mice. B, Microstructural parameters are shown. BV/TV, Three-dimensional-bone volume fraction per tissue volume; Conn-Dens, connectivity density; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; SMI, structure model index. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  vs. WT ( $n = 7-9$  for each group).




FIG. 4. GGT-Tg mice exhibit elevated bone resorption with reduced bone formation. Results of histomorphometry at the tibial metaphysis are shown. Note that GGT-Tg mice exhibit increases in indices of bone resorption (N.Oc, number of osteoclasts; Oc.S, osteoclast surface; ES, eroded surface) and decreases in parameters of bone formation (BFR, bone formation rate; Ob.S, osteoblast surface; MAR, mineral apposition rate). Data are normalized for bone surface (BS). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  vs. WT ( $n = 5$  for each group).

type mice. Unexpectedly, the GGT-Tg mice revealed a lowered bone formation rate (BFR) with reduced osteoblast surface (Ob.S) and mineral apposition rate (MAR) (Fig. 4). Taken together with the elevated DPD excretion in GGT-Tg mice, these data suggest systemic overproduction of GGT accelerates bone resorption while suppressing bone formation, thus resulting in osteopenia.

#### Mechanism of accelerated bone resorption in GGT-Tg mouse

To gain further insight into the mechanism by which GGT stimulates osteoclast formation and bone resorption, we crossed GGT-Tg with mice lacking RANKL, an essential cytokine for osteoclastogenesis. Transgenic expression of GGT caused osteopenia on a RANKL<sup>+/-</sup> background (Fig. 5). Homozygous KO (RANKL<sup>-/-</sup>) mice exhibited typical osteopetrosis with failure of tooth eruption and a complete absence of TRAP-positive osteoclasts, and GGT overexpression did not rescue these animals from the abnormal phenotypes in the absence of RANKL (Fig. 5). These results provide genetic evidence that RANKL is required for GGT to induce bone resorption.

Based on these findings, we investigated GGT modulation of the cellular response to RANKL in the presence of M-CSF. As shown in Fig. 6A, bone marrow macrophages derived from GGT-Tg mice gave rise to more and larger TRAP-positive multinucleate cells in response to RANKL, and quantitation of TRAP-positive cells with more than three nuclei indicated that the bone marrow macrophages from GGT-Tg mice generated significantly more osteoclasts than those from wild-type mice in response to RANKL. The TRAP-positive cells thus formed were functional, and those derived from GGT-Tg mice produced significantly more pits on dentin slices (Fig. 6B). These results suggest that GGT stimulates bone resorption by modulating the signaling of RANKL in osteoclast precursor cells of monocyte-macrophage lineage.

To further substantiate this concept, we extracted RNA from bone marrow cells and bone cells (cells attached to bone after flushing out the bone marrow) from both GGT-Tg and wild-type mice, and gene expression was examined by quantitative




FIG. 5. RANKL is required for GGT to induce osteoclast formation. GGT-Tg mice were crossed with RANKL<sup>+/-</sup> mice to obtain the indicated genotypes. Representative micro-CT images of trabecular compartments of proximal tibiae are shown with the bone volume fraction (BV/TV) and the presence or absence of tooth eruption in the respective genotype. GGT-Tg induces osteopenia as a result of stimulated bone resorption on a RANKL<sup>+/-</sup> background, whereas GGT overexpression does not rescue RANKL<sup>-/-</sup> mice from their osteoclast-deficiency phenotypes, *i.e.* osteopetrosis and failure of tooth eruption.





FIG. 6. GGT increases the sensitivity of bone marrow macrophages to RANKL. A, Bone marrow macrophages derived from GGT-Tg mice generated more and larger TRAP-positive osteoclasts than those from wild-type (WT) bone marrow in response to RANKL. *Ex vivo* culture was performed in the presence of M-CSF and RANKL, and the number of TRAP-positive cells with more than three nuclei was counted. B, Preosteoclasts were prepared from the bone marrow macrophages from GGT-Tg and WT mice in the presence of M-CSF and RANKL for 2 d, and then cells were incubated on dentin slices for 2 d. Resorption pits were stained with Coomassie brilliant blue. \*\*,  $P < 0.01$  vs. WT ( $n = 3$  for each group). C, Recombinant human GGT (rhGGT) stimulated osteoclast formation in a dose-dependent manner. Bone marrow macrophages were cultured with M-CSF (50 ng/ml) and RANKL (25 ng/ml) in the absence or presence of the indicated concentrations of recombinant GGT protein. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  vs. control cultures without GGT ( $n = 3$  for each group). D, Recombinant human GGT (rhGGT) stimulated RANKL expression. Marrow stromal cells were treated with increasing concentrations of recombinant GGT protein, and RANKL mRNA expression was analyzed by RT-PCR. GAPDH mRNA was used as an internal control.

RT-PCR. As shown in Fig. 7, expression levels of RANKL mRNA in the bone fraction and RANK mRNA in bone marrow cells did not differ significantly between the GGT-Tg and wild-type mice. In contrast, bone marrow cells from GGT-Tg mice exhibited significantly higher expression of *c-fos*, *c-jun*, and *NFATc1* mRNA, which are transcription factors essential for osteoclastogenesis (22–24) (Fig. 7). The finding that critical positive regulators known to transmit the osteoclastogenic signal from the RANK receptor are up-regulated in bone marrow cells of GGT-Tg mice, although the expression of RANKL and RANK are unaltered, supports the concept that GGT acts on hematopoietic cells of monocyte-macrophage lineage to increase their sensitivity to RANKL, thereby stimulating osteoclast generation and bone resorption. Also consistent with this



FIG. 7. Increased expression of c-Fos, c-Jun, and NFATc1 mRNA in GGT-Tg marrow cells. Expression of critical regulators of osteoclast differentiation (RANKL in bone fraction and other molecules in bone marrow fraction) in GGT-Tg vs. wild-type (WT) mice was examined. RNA was extracted from bone and bone marrow separately from three wild-type and three Tg mice, and mRNA levels were determined by quantitative RT-PCR. \*\*,  $P < 0.01$  vs. wild type.



notion are the results that recombinant GGT protein was capable of stimulating osteoclast formation from bone marrow macrophages in a dose-dependent manner, and a significant increase in osteoclastogenesis was observed at 30 ng/ml (Fig. 6C). As reported previously (9), recombinant GGT also increased the expression of RANKL mRNA in marrow stromal cells but only at the highest concentration of 100 ng/ml (Fig. 6D).

GGT-Tg mice produce GGT not only in skeletal tissue but also in various other tissues and exhibit elevated levels of circulating GGT (Fig. 2, A and D). To rule out the possibility that bone resorption was stimulated as a secondary effect of systemic overexpression of GGT and to obtain evidence that GGT acts locally in bone, we next generated transgenic lines that produce GGT only in bone tissue. Taking advantage of the original design of our floxed eGFP-GGT construction (Fig. 1A), which enables tissue-specific expression of GGT, we crossed floxed eGFP-GGT mice with Col I-Cre mice, which express Cre recombinase under the control of the 2.3-kb type I collagen promoter and have been shown to target transgenic expression specifically in osteoblasts (16), to generate Col I-GGT mice. The serum GGT concentration of Col I-GGT mice was not increased (<2 IU/liter), compared with the floxed eGFP-GGT mice used as a control, indicating that Col I-GGT mice are not characterized by systemic overproduction of GGT. TRAP staining of tibial sections revealed that significantly more TRAP-positive multinucleate osteoclasts were induced in the skeletal tissue of Col I-GGT mice than floxed eGFP-GGT mice (Fig. 8A). These results suggest that systemic elevation of GGT is not a prerequisite for its osteoclastogenic action and are consistent with the concept that GGT acts locally on bone in stimulating osteoclast formation.

To determine whether the enzymatic activity is required for the bone-resorbing activity, we introduced mutations in two consecutive serine residues at 451 and 452, which are known to be critical for the catalytic activity, by substituting them with alanine (S451A/S452A double mutant). When the point-mutated GGT (pmtGGT) was expressed in HEK293 cells at the same level as the wild-type molecule, the enzyme activity was barely detectable in the conditioned medium or in whole cell extract (Fig. 8B). We then introduced the wild-type or S451A/S452A GGT into bone marrow macrophages through retroviral infection and assessed their osteoclastogenic potential. The results indicate that mutant GGT with essentially no enzyme activity induced osteoclast formation as potently as the wild-type GGT (Fig. 8C). Thus, these results can be taken as evidence that GGT can induce osteoclast development independently of its enzyme activity and raise the possibility that GGT acts as a cytokine on hematopoietic cells in the bone marrow. When the


wild-type or pmtGGT was introduced into primary osteoblasts by retroviral infection, both molecules reduced alkaline phosphatase activity (Fig. 8D), suggesting that GGT can act directly on osteoblasts to suppress their differentiation.

## Discussion

GGT is recognized as a marker of alcohol consumption and liver disease, and increased serum GGT enzyme activity is a biochemical hallmark of patients with alcoholism, fatty liver disease, and biliary tract disorders such as primary biliary cirrhosis (25). Although it is known that these clinical conditions are risk factors for or complicated by skeletal abnormalities (26–28), the underlying molecular mechanisms are not fully understood. It is demonstrated in the present study that an excess of GGT causes osteopenia and microstructural deterioration characteristic of osteoporosis through an acceleration of osteoclast generation and bone resorption. The serum GGT concentrations in the transgenic model in this study are in the range of 200 IU/liter, a level often seen in individuals with moderately excessive alcohol consumption and in patients with liver and biliary tract diseases. Together with our *in vitro* data showing that purified GGT protein at 100 IU/liter is capable of inducing osteoclast formation in bone marrow cultures (9), it is likely that even moderately elevated circulating levels of GGT would contribute to the bone loss associated with these conditions.

Whereas serum GGT activity derives mainly from the liver, GGT is abundantly expressed in the kidney, pancreas, seminal vesicle, and small intestine, where this ectoenzyme is located on the apical membrane (11). GGT is anchored to the plasma membrane with most of the molecule exposed to extracellular space (11) and is thought to be released by shedding into the serum as well as urine (29), although the exact molecular form in the extracellular fluid as well as the mechanism of shedding remains to be determined. GGT catalyzes the transfer of a  $\gamma$ -glutamyl moiety to an acceptor and plays a critical role in glutathione degradation and cysteine metabolism (10, 11). Mice deficient in GGT exhibit accelerated aging, such as gray fur, cataracts, sexual dysfunction, and severe osteoporosis, and die at the early age of 10–18 wk due to the lack of GGT enzyme activity and the resultant cysteine deficiency (12, 13). Osteopenia in GGT-deficient mice is associated with decreased bone formation, which is treatable by supplementation with *N*-acetylcysteine, suggesting that GGT also plays an important physiological role in regulating bone formation through cysteine metabolism (13). Taken together with the current results, both a deficiency and an excess of GGT result in osteoporosis. However, the osteoporosis is exerted through distinct mechanisms;





**FIG. 8.** GGT acts on osteoclast precursors and stimulates osteoclastogenesis independently of its enzyme activity. **A**, Floxed eGFP-GGT mice were crossed with Col I-Cre mice to generate Col I-GGT mice that expressed GGT specifically in their osteoblasts. The results of staining for TRAP in tibial sections from Col I-GGT mice and floxed eGFP-GGT mice as a control are shown. The number of TRAP-positive multinucleate cells (MNCs) was counted. \*,  $P < 0.05$  vs. wild-type ( $n = 3$  for each group). **B** and **C**, pmtGGT with defective enzymatic activity is capable of inducing osteoclast differentiation. S451A/S452A double-mutated GGT (pmtGGT) was introduced into HEK293 cells at the same level as the wild-type (WT) protein, and GGT activity in the conditioned media and cell lysates was determined (**B**). Bone marrow macrophages were infected with retroviral vectors encoding WT-GGT or pmtGGT and cultured in the presence of M-CSF and RANKL, after which the cells were stained for TRAP activity (**C**). Note that pmtGGT as well as WT-GGT generated more and larger TRAP-positive osteoclasts. \*\*,  $P < 0.01$  vs. vector-infected cultures ( $n = 4$  for each group). **D**, Primary osteoblasts isolated from the calvaria were infected with retroviral vectors encoding WT-GGT or pmtGGT and cultured under osteogenic conditions, after which the cells were stained for alkaline phosphatase activity.

*i.e.* the former is caused by suppression of bone formation due to systemic deficiency in enzymatic activity, whereas the latter is mainly due to an acceleration of bone resorption by an excess of GGT, which is independent of the enzyme activity and reflects a local effect. The latter nonenzymatic activity of GGT may have been masked by the gene knockout, and appreciating its physiological importance would require the identification of its mediator, possibly the putative receptor.

The results of experiments exploiting targeted overexpression of GGT in osteoblasts driven by a type I collagen promoter suggest not only systemic elevation of GGT but also local production of GGT is sufficient to stimulate osteoclast develop-

ment. The findings that retroviral transduction of GGT as well as the addition of recombinant GGT protein in bone marrow macrophages stimulates osteoclastogenesis and that bone marrow macrophages from GGT-Tg mice stimulate increased osteoclasts in *ex vivo* cultures further support the concept that hematopoietic cells, especially those of monocyte/macrophage lineage, are the target of GGT in bone. Two cytokines, M-CSF and RANKL, are essential for these progenitor cells to undergo terminal differentiation to become mature, bone-resorbing osteoclasts. Genetic evidence has been obtained by crossing GGT-Tg with RANKL-deficient mice, which shows RANKL is required for GGT action, because GGT is not able to induce osteoclastogenesis in the absence of RANKL. Furthermore, our data show osteoclast progenitor cells from GGT-Tg mice exhibit an enhanced responsiveness to RANKL, resulting in increased generation of osteoclasts at the cellular level and increased expression of critical regulators of osteoclastogenesis, *i.e.* c-Fos, c-Jun, and nuclear factor of activated T cells (NFATc1), at the molecular level. The finding that neither RANKL expression in stromal cells nor RANK expression in bone marrow cells is altered in the presence of an excess of GGT further supports the concept that GGT modulates the signal transduction pathway after RANKL has bound RANK on the surface of osteoclast progenitors. We previously reported the addition of purified GGT protein to marrow stromal cells increased RANKL mRNA and protein at 3 d post addition, which prompted us to hypothesize that GGT stimulates osteoclast formation indirectly through increased RANKL expression (9). The stimulatory effect of GGT on RANKL expression in marrow stromal cells has been confirmed in the current study using recombinant GGT protein but needed a greater concentration (100 ng/ml) than the minimal concentration that exerted the direct effect on bone marrow macrophages (30 ng/ml). Thus, although the exact reason for the difference between these findings and the unaltered RANKL expression in the stromal cells of GGT-Tg mice is not clear, it is likely that hematopoietic cells are more sensitive to the GGT effect than are stromal cells. Also, differences in the molecular form of GGT and/or its duration of action (*i.e.* days in the *in vitro* cultures vs. the chronic overexpression for a period of months in the transgenic mice) may be involved. GGT is similar to TGF- $\beta$  in that both cytokines enhance osteoclast differentiation from hematopoietic cells in response to RANKL (30). However, GGT is dissimilar to TGF- $\beta$  in that GGT stimulates RANKL expression, whereas TGF- $\beta$  decreases RANKL and increases OPG expression in stromal cells (31), resulting in complex effects on osteoclastic bone resorption.

Finally and most importantly, the osteoclastogenic function of GGT does not require its enzymatic activity, because the introduction of point mutations in the amino acids critical for enzyme activity had no effect on the osteoclast-inducing activity. These results suggest that a functional domain of GGT required for stimulating osteoclast differentiation is dissociable from its enzymatic activity, and raise the intriguing potential of GGT acting as a local osteoclastogenic cytokine through interaction with a receptor molecule. Alternatively, GGT may modulate the availability of RANKL to RANK through protein-protein interaction. Additional studies are required to identify the putative GGT receptor on osteoclast progenitor cells and to determine whether GGT converges on signaling pathways downstream of the RANK receptor in a cell-autonomous fash-

ion or whether GGT action is mediated indirectly through yet another extracellular signaling molecule.

In conclusion, this study has uncovered a novel function for GGT in the regulation of osteoclast development. This does not require the enzyme activity and may represent a novel mode of action as a cytokine. Given the involvement of GGT in bone and joint diseases characterized by accelerated osteoclast development, GGT may be a novel target for the development of diagnostics and therapeutics.

### Acknowledgments

We thank Drs. Yoshitaka Ikeda (Saga University), Naoyuki Taniguchi (Osaka University), and Yasuyuki Ishizuka (Applied Cell Biotechnologies, Inc.) for valuable suggestions and anti-GGT antibody; Dr. Tatsuo Suda (Research Center for Genomic Medicine, Saitama Medical School) for critical reading of the manuscript; Dr. Jun-ichi Miyazaki (Osaka University) for providing the CAG-Cre mice; Dr. Josef Penninger for the RANKL KO mice; Dr. Noboru Motoyama (NCGG) for advice on transgenic construction; Ms. Kumi Tsutsumi and Mrs. Mie Suzuki for technical assistance; members of our Department (NCGG) for stimulating discussion; and Drs. Akihiro Yasui and Shinji Fukada (National Hospital for Geriatric Medicine, NCGG) and Dr. Toshiyuki Arai (Department of Surgery, Nagoya University School of Medicine) for encouragement and support throughout the study. Pacific Edit reviewed the manuscript before submission.

Received February 14, 2007. Accepted March 5, 2007.

Address all correspondence and requests for reprints to: Kyoji Ikeda, M.D., at Department of Bone and Joint Disease, Research Institute, National Center for Geriatrics and Gerontology (NCGG), 36-3 Gengo, Morioka, Obu, Aichi 474-8522, Japan. E-mail: kiked@nls.go.jp.

This work was supported by a grant-in-aid for Longevity Science from the Ministry of Health and Welfare of Japan (to K.I.) and a grant for the Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan (MF-14 and 06-31 to K.I.).

The authors have nothing to disclose.

### References

- Cummings SR, Melton LJ 2002 Epidemiology and outcomes of osteoporotic fractures. *Lancet* 359:1761–1767
- Lee DM, Weinblatt ME 2001 Rheumatoid arthritis. *Lancet* 358:903–911
- Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. *Nat Rev Genet* 4:638–649
- Karsenty G, Wagner EF 2002 Reaching a genetic and molecular understanding of skeletal development. *Dev Cell* 2:389–406
- Firestein GS 2003 Evolving concepts of rheumatoid arthritis. *Nature* 423:356–361
- Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. *Nature* 423:337–342
- Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature* 397:315–323
- Ishiduka Y, Mochizuki R, Yanai K, Takatsuka M, Nonomura T, Niida S, Horiguchi H, Maeda N, Fukamizu A 1999 Induction of hydroxyapatite resorptive activity in bone marrow cell populations resistant to bafilomycin A1 by a factor with restricted expression to bone and brain, neurochondrin. *Biochim Biophys Acta* 1450:92–98
- Niida S, Kawahara M, Ishizuka Y, Ikeda Y, Kondo T, Hibi T, Suzuki Y, Ikeda K, Taniguchi N 2004  $\gamma$ -Glutamyltranspeptidase stimulates receptor activator of nuclear factor- $\kappa$ B ligand expression independent of its enzymatic activity and serves as a pathological bone-resorbing factor. *J Biol Chem* 279:5752–5756
- Lieberman MW, Barrios R, Carter BZ, Habib GM, Lebovitz RM, Rajagopalan S, Sepulveda AR, Shi ZZ, Wan DF 1995  $\gamma$ -Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? *Am J Pathol* 147:1175–1185
- Taniguchi N, Ikeda Y 1998  $\gamma$ -Glutamyl transpeptidase: catalytic mechanism and gene expression. *Adv Enzymol Relat Areas Mol Biol* 72:239–278
- Lieberman MW, Wiseman AL, Shi ZZ, Carter BZ, Barrios R, Ou CN, Chevez-Barrios P, Wang Y, Habib GM, Goodman JC, Huang SL, Lebovitz RM, Matzuk MM 1996 Growth retardation and cysteine deficiency in  $\gamma$ -glutamyl transpeptidase-deficient mice. *Proc Natl Acad Sci USA* 93:7923–7926
- Levasseur R, Barrios R, Eleftheriou F, Glass 2nd DA, Lieberman MW, Karsenty G 2003 Reversible skeletal abnormalities in  $\gamma$ -glutamyl transpeptidase-deficient mice. *Endocrinology* 144:2761–2764
- Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, Motoyama N 2002 FOXO forkhead transcription factors induce G<sub>2</sub>-M checkpoint in response to oxidative stress. *J Biol Chem* 277:26729–26732
- Sakai K, Miyazaki J 1997 A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. *Biochem Biophys Res Commun* 237:318–324
- Dacquin R, Starbuck M, Schinke T, Karsenty G 2002 Mouse  $\alpha$ 1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. *Dev Dyn* 224:245–251
- Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K 2006 c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. *J Clin Invest* 116:528–535
- Ito M, Ikeda K, Nishiguchi M, Shindo H, Uetani M, Hosoi T, Orimo H 2005 Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk. *J Bone Miner Res* 20:1828–1836
- Meister A, Tate SS, Griffith OW 1981  $\gamma$ -Glutamyl transpeptidase. *Methods Enzymol* 77:237–253
- Takehita S, Namba N, Zhao JJ, Jiang Y, Genant HK, Silva MJ, Brodt MD, Helgason CD, Kalesnikoff J, Rauh MJ, Humphries RK, Krystal G, Teitelbaum SL, Ross FP 2002 SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. *Nat Med* 8:943–949
- Ikeda Y, Fujii J, Taniguchi N, Meister A 1995 Expression of an active glycosylated human  $\gamma$ -glutamyl transpeptidase mutant that lacks a membrane anchor domain. *Proc Natl Acad Sci USA* 92:126–130
- Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF 2000 Fos1 is a transcriptional target of c-Fos during osteoclast differentiation. *Nat Genet* 24:184–187
- Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T 2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. *Dev Cell* 3:889–901
- Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T 2004 Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. *J Clin Invest* 114:475–484
- Kaplan MM, Gershwin ME 2005 Primary biliary cirrhosis. *N Engl J Med* 353:1261–1273
- Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A 2005 Alcohol intake as a risk factor for fracture. *Osteoporos Int* 16:737–742
- Felson DT, Kiel DP, Anderson JJ, Kannel WB 1988 Alcohol consumption and hip fractures: the Framingham Study. *Am J Epidemiol* 128:1102–1110
- Mankin HJ 1992 Nontraumatic necrosis of bone (osteonecrosis). *N Engl J Med* 326:1473–1479
- Asaba Y, Hiramatsu K, Matsui Y, Harada A, Nimura Y, Katagiri N, Kobayashi T, Takewaka T, Ito M, Niida S, Ikeda K 2006 Urinary  $\gamma$ -glutamyltransferase (GGT) as a potential marker of bone resorption. *Bone* 39:1276–1282
- Sells Galvin RJ, Gatlin CL, Horn JW, Fuson TR 1999 TGF- $\beta$  enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. *Biochem Biophys Res Commun* 265:233–239
- Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y 1998 Transforming growth factor- $\beta$  stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. *J Biol Chem* 273:27091–27096

*Endocrinology* is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

# Akt1 in Osteoblasts and Osteoclasts Controls Bone Remodeling

Naohiro Kawamura<sup>1</sup>, Fumitaka Kugimiya<sup>1</sup>, Yasushi Oshima<sup>1</sup>, Shinsuke Ohba<sup>2</sup>, Toshiyuki Ikeda<sup>1</sup>, Taku Saito<sup>1</sup>, Yusuke Shinoda<sup>1</sup>, Yosuke Kawasaki<sup>1</sup>, Naoshi Ogata<sup>1</sup>, Kazuto Hoshi<sup>1</sup>, Toru Akiyama<sup>1</sup>, William S. Chen<sup>3</sup>, Nissim Hay<sup>4</sup>, Kazuyuki Tobe<sup>5</sup>, Takashi Kadowaki<sup>5</sup>, Yoshiaki Azuma<sup>6</sup>, Sakae Tanaka<sup>1</sup>, Kojo Nakamura<sup>1</sup>, Ung-il Chung<sup>2</sup>, Hiroshi Kawaguchi<sup>1\*</sup>

**1** Department of Sensory and Motor System Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan, **2** Center for Disease Biology and Integrative Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan, **3** Transgenic and Knockout Mouse Laboratory, University of Kansas, Lawrence, Kansas, United States of America, **4** Department of Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America, **5** Department of Metabolic Diseases, Faculty of Medicine, University of Tokyo, Tokyo, Japan, **6** Teijin Institute for Biomedical Research, Tokyo, Japan

Bone mass and turnover are maintained by the coordinated balance between bone formation by osteoblasts and bone resorption by osteoclasts, under regulation of many systemic and local factors. Phosphoinositide-dependent serine-threonine protein kinase Akt is one of the key players in the signaling of potent bone anabolic factors. This study initially showed that the disruption of Akt1, a major Akt in osteoblasts and osteoclasts, in mice led to low-turnover osteopenia through dysfunctions of both cells. *Ex vivo* cell culture analyses revealed that the osteoblast dysfunction was traced to the increased susceptibility to the mitochondria-dependent apoptosis and the decreased transcriptional activity of runt-related transcription factor 2 (Runx2), a master regulator of osteoblast differentiation. Notably, our findings revealed a novel role of Akt1/forkhead box class O (FoxO) 3a/Bim axis in the apoptosis of osteoblasts: Akt1 phosphorylates the transcription factor FoxO3a to prevent its nuclear localization, leading to impaired transactivation of its target gene Bim which was also shown to be a potent proapoptotic molecule in osteoblasts. The osteoclast dysfunction was attributed to the cell autonomous defects of differentiation and survival in osteoclasts and the decreased expression of receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), a major determinant of osteoclastogenesis, in osteoblasts. Akt1 was established as a crucial regulator of osteoblasts and osteoclasts by promoting their differentiation and survival to maintain bone mass and turnover. The molecular network found in this study will provide a basis for rational therapeutic targets for bone disorders.

Citation: Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, et al (2007) Akt1 in Osteoblasts and Osteoclasts Controls Bone Remodeling. *PLoS ONE* 2(10): e1058. doi:10.1371/journal.pone.0001058

## INTRODUCTION

Bone is continually remodeled according to physiological circumstances through bone formation by osteoblasts and bone resorption by osteoclasts, and bone mass and turnover are maintained by their coordinated balance in healthy adults. Many systemic and local factors are involved in the regulation [1,2], among which insulin, insulin-like growth factor-I (IGF-I), bone morphogenetic factors (BMPs), and Wnt proteins are potent bone anabolic factors [3–6]. A serine-threonine kinase Akt, also called protein kinase B (PKB), is known as a potent signal transducer of these bone anabolic factors [7–9].

There are three Akt family members, Akt1/PKB $\alpha$ , Akt2/PKB $\beta$  and Akt3/PKB $\gamma$ . Akt1 and Akt2, but not Akt3, are reported to be ubiquitously and similarly expressed in various tissues, although Akt2 is expressed more predominantly in insulin target tissues such as fat, liver and muscle [9,10]. Accordingly, Akt1<sup>-/-</sup> mice and Akt2<sup>-/-</sup> mice show similar phenotypes including dwarfism, except that only the latter exhibit severe diabetes [10–13]. Although phenotype of mice lacking single Akt isoform is relatively mild possibly due to functional redundancy of the remaining isoforms, double-knockout of Akt1 and Akt2 in mice causes severely impaired bone development and death shortly after birth [14]. The abnormalities of these knockout mice certainly imply a crucial commitment of Akt signals to bone metabolism, yet it has remained unknown whether or not these were due to the cell autonomous effects of the Akt deficiency on bone cells. To elucidate the physiological role of the Akt signaling in the regulation of bone formation and resorption, the present study initially analyzed the bones of mice lacking Akt1, a major Akt isoform in bone, and found that the deficiency caused osteopenia

with a low turnover state. We further investigated the underlying cellular and molecular mechanisms in osteoblasts and osteoclasts.

## RESULTS

### Akt1 is a major isoform in bone cells

We initially confirmed that the total Akt (Akt1–3) was phosphorylated by osteogenic factors IGF-I and BMP-2 in cultured osteoblasts, and by a bone resorptive macrophage colony-stimulating factor (M-CSF) in osteoclast-progenitor bone marrow macrophages (BMM) and mature osteoclasts (Supp. Fig S1A). Among the three Akt isoforms, Akt1 and Akt2 were highly expressed in these bone cells (Supp. Fig S1B).

Academic Editor: Thomas Zwaka, Baylor College of Medicine, United States of America

Received May 8, 2007; Accepted August 14, 2007; Published October 24, 2007

Copyright: © 2007 Kawamura et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by a Grant-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (#17390410). The sponsor had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Competing Interests: The authors have declared that no competing interests exist.

\* To whom correspondence should be addressed. E-mail: kawaguchi-ort@h.u-tokyo.ac.jp

## Akt1 deficiency causes decreased bone mass and formation

To investigate the physiological role of the Akt signaling in bone, we examined the bone phenotype of Akt1 deficient (Akt1<sup>-/-</sup>) mice, because Akt1; Akt2 double-knockout mice die shortly after birth [14]. Akt1<sup>-/-</sup> mice were healthy and fertile without abnormality in major organs or skeletal patterning, but were smaller in size compared to the wild-type (WT) littermates (Supp. Fig S2) as previously reported [11]. Radiological analyses of long bones in 8 week-old mice using plain X-ray, bone mineral density (BMD) analysis (Fig 1A), three dimensional (3D) CT (Fig 1B), and peripheral quantitative CT (pQCT) (Fig 1C) revealed decreases in both trabecular and cortical bones as a result of the Akt1 deficiency. Although the growth plate was not affected (Fig 1D), bone formation parameters (MAR&BFR) of the trabecular bone were decreased (Fig 1E), indicating that osteopenia in the Akt1<sup>-/-</sup> mice was at least partly due to the impairment of osteoblastic bone formation. This defect was accompanied by a decrease in the number of osteoblasts shown by the percentage of bone surface covered by cuboidal osteoblasts (Ob.S/BS) and an increase in that of apoptotic osteoblasts shown by terminal deoxynucleotidyl transferase mediated dUTP nick-end-labeling (TUNEL)-positive cells (Fig 1E).

## Akt1 deficiency enhances susceptibility to apoptosis of osteoblasts via FoxO3a

To learn the mechanism of impaired bone formation, we compared *ex vivo* functions of osteoblasts isolated from WT and Akt1<sup>-/-</sup> littermates. We first confirmed that both phosphorylated and unphosphorylated Akt proteins were considerably decreased in cultured Akt1<sup>-/-</sup> osteoblasts without compensatory increase of Akt2 protein, indicating a substantial suppression of the total Akt signaling by depletion of an isoform Akt1 in osteoblasts (Fig 2A). Although cell proliferation was not affected (Fig 2B), cell survival after serum deprivation was decreased by the Akt1 deficiency (Fig 2C). This decrease was confirmed to be due to the enhanced susceptibility to apoptosis of osteoblasts by TUNEL staining (Fig 2D). Caspase-3 activity and the cleaved active form was enhanced in Akt1<sup>-/-</sup> osteoblasts, which was restored by adenoviral introduction of a constitutively active form of Akt1 (Akt1<sup>CA</sup>) or Bcl-x<sub>L</sub>, a specific inhibitor of mitochondria-dependent apoptosis [15] (Fig 2E). Hence, Akt1 deficiency in osteoblasts is not likely to affect the proliferation, but suppresses the survival through an enhanced susceptibility to mitochondria-dependent apoptosis.

Among apoptosis-related molecules that have been reported to be possible substrates of Akt [9,16], transcription factors FoxO3a and FoxO1, and a proapoptotic molecule Bad were expressed in primary osteoblasts and osteoblastic cell line MC3T3-E1 (Fig 2F). Since phosphorylation of FoxO proteins is known to result in their nuclear exclusion in other types of cells [16], we confirmed the nuclear entry of FoxO3a after serum deprivation in MC3T3-E1 cells (Supp. Fig S3). The nuclear localization of FoxO3a was more enhanced in Akt1<sup>-/-</sup> osteoblasts than in WT after serum deprivation (Fig 2G). This correlated with the decrease of the upper band and the increase of the lower band in the cytoplasmic fraction of the immunoblotting, which were proved to be phosphorylated and unphosphorylated FoxO3a, respectively, since the upper one was enhanced by FBS and eliminated by lambda protein phosphatase (Fig 2H). Meanwhile, Akt1 overexpression by Akt1<sup>CA</sup> transfection in osteoblasts stimulated the cytoplasmic FoxO3a phosphorylation and inhibited the nuclear entry (Fig 2I). Contrarily, subcellular localization of FoxO1 was not affected by the Akt1 deficiency (Fig 2G), nor was phosphorylated Bad protein

detected in osteoblasts, probably due to its low level (data not shown). Finally, the decreased survival rate and the increased caspase-3 activity of Akt1<sup>-/-</sup> osteoblasts after serum deprivation were restored by introduction of a dominant-negative form of FoxO3a (FoxO3a<sup>DN</sup>) (Fig 2J, K).

The lines of results indicate that a transcription factor FoxO3a is a phosphorylation target of Akt1 in the anti-apoptotic action on osteoblasts, so that the Akt1 deficiency attenuates FoxO3a phosphorylation and nuclear exclusion, which leads to the enhanced transcriptional activity somehow causing apoptosis.

## Akt1 suppresses osteoblast apoptosis through inhibition of FoxO3a and Bim

We next sought to identify the transcriptional target of FoxO3a that lies downstream of the Akt1 anti-apoptotic signaling in osteoblasts. Among the candidate molecules Fas ligand, Bim, and Bcl-x<sub>L</sub> that were reported previously in other tissues [17], only Bim mRNA level was increased after serum deprivation in osteoblasts (Fig 3A). Bim protein level was also increased, followed by the induction of cleaved caspase-3, while none of the major regulators of mitochondria-dependent apoptosis: proapoptotic Bax, anti-apoptotic Bcl-2 and Bcl-x<sub>L</sub> [15], was affected by serum deprivation (Fig 3B). The cleaved caspase-3 induction was mediated by Bim, since it was suppressed by silencing of Bim through RNA interference (Fig 3C). Actinomycin D, an inhibitor of RNA transcription, canceled the Bim increase after serum deprivation, indicating that this is a transcriptional induction (Supp. Fig S4A, B). The Bim promoter activity was actually enhanced by FoxOs, among which FoxO3a exhibited the strongest transactivity (Fig 3D). Endogenous Bim expression was confirmed to be enhanced by FoxO3a overexpression and attenuated by the suppression (Fig 3E, F). These results indicate that Bim is a transcriptional target of FoxO3a in osteoblasts.

We then looked at the involvement of Akt1 in the FoxO3a and Bim interaction in osteoblasts. Gain-of-function of Akt1 by Akt1<sup>CA</sup> transfection abrogated the stimulation of the Bim promoter activity by FoxO3a (Fig 3G). The induction of endogenous Bim after serum deprivation was also suppressed by Akt1<sup>CA</sup> (Fig 3H) as well as by insulin or IGF-I, potent activators of the Akt signaling (Supp. Fig S4C). Finally, the Bim expression in Akt1<sup>-/-</sup> osteoblasts was higher than that in WT osteoblasts, which was restored by the FoxO3a<sup>DN</sup> transfection (Fig 3I).

Taken together, we conclude that Akt1 phosphorylates FoxO3a to prevent it from translocating into nucleus, which leads to suppression of Bim transactivation and osteoblast apoptosis.

## Akt1 deficiency impairs Runx2-dependent differentiation and function of osteoblasts

Since the *in vivo* histomorphometric analysis of the Akt1<sup>-/-</sup> bone (Fig 1E) showed not only a decrease in osteoblast number, but also a decrease in the ability of an individual osteoblast to form bone (MAR), we performed *ex vivo* analyses of the effects of Akt1 deficiency on osteoblast differentiation and function, in addition to their proliferation and apoptosis. The differentiation determined by alkaline phosphatase (ALP) activity was impaired in Akt1<sup>-/-</sup> osteoblasts in the control and stimulated cultures by insulin or IGF-I, but not by BMP-2 (Fig 4A). Differentiation markers type I collagen, ALP, bone sialoprotein, osteocalcin, Runx2 and osterix were also decreased by Akt1 deficiency in osteoblasts (Fig 4B). This was a cell autonomous function of Akt1 since the impaired differentiation and matrix synthesis shown by ALP and Alizarin red stainings in the Akt1<sup>-/-</sup> osteoblast culture were restored by introduction of Akt1<sup>CA</sup> (Fig 4C). Interestingly, the Akt1<sup>CA</sup>